POSEIDON Trial Phase 1b Results: Safety, Efficacy and...

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Baird, Richard D., van Rossum, Annelot G.J., Oliveira, Mafalda, Beelen, Karin, Gao, Meiling, Schrier, Mariette, Mandjes, Ingrid A.M., Garcia-Corbacho, Javier, Vallier, Anne-Laure, Dougall, Greig, van
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
25
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-19-0508
Date:
November, 2019
File:
PDF, 730 KB
english, 2019
Conversion to is in progress
Conversion to is failed